Wolverine Trading’s Cytokinetics CYTK Stock Holding History

Wolverine Trading’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$1.05M	Sell	19,500 -16,300	-46%	-$672K	﹤0.01%	2857
2025 Q2	$1.19M	Buy	35,800 +10,500	+42%	+$365K	﹤0.01%	2148
2025 Q1	$1.09M	Buy	25,300 +6,000	+31%	+$276K	﹤0.01%	2163
2024 Q4	$910K	Sell	19,300 -100	-0.5%	-$5.19K	﹤0.01%	2760
2024 Q3	$1.02M	Buy	19,400 +9,200	+90%	+$513K	﹤0.01%	2338
2024 Q2	$553K	Sell	10,200 -11,600	-53%	-$700K	﹤0.01%	2737
2024 Q1	$1.53M	Sell	21,800 -14,400	-40%	-$1.11M	﹤0.01%	1823
2023 Q4	$3.02M	Buy	+36,200	New	+$1.31M	﹤0.01%	1396

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Wolverine Trading's CYTK Position: Q3 2025 in Review

Wolverine Trading reduced its Cytokinetics (CYTK) stake by 45% in Q3 2025, selling an estimated $480K and leaving 14,150 shares worth $763K. The position accounts for ﹤0.01% of the portfolio, ranked #3197.

Wolverine Trading first reported a position in CYTK in Q4 2023 and has held it in 6 quarters since. The position peaked at $861K in Q4 2023. 380 funds tracked by Wall St. Rank hold CYTK as of Q3 2025.

Wolverine Trading held 14,150 shares of Cytokinetics worth $763K as of Q3 2025.
Wolverine Trading sold 11,658 Cytokinetics shares in Q3 2025, an estimated $480K.
Cytokinetics made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #3197 holding.
Wolverine Trading first reported a position in Cytokinetics in Q4 2023 and has held it in 6 quarters since.
Wolverine Trading's Cytokinetics position peaked at $861K in Q4 2023.
380 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.